InMed Pharmaceuticals (INM) announced the “successful” completion of pharmacokinetic studies in large animal models for its Alzheimer’s disease candidate INM-901. “This marks the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program,” the company stated.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INM:
- InMed Completes Key Pharmacokinetic Studies for Alzheimer’s Candidate INM-901
- InMed Pharmaceuticals Reports Q3 2025 Financial Results
- InMed Pharmaceuticals Advances Alzheimer’s Program Amidst Strong Fiscal Start
- InMed Pharmaceuticals Strengthens Board with Strategic Appointment
- InMed Pharmaceuticals Strengthens Board with Appointment of Industry Veteran Neil Klompas